The Global Prostate-Specific Antigen Test Market was valued at USD 5.1 billion in 2025 and is estimated to grow at a CAGR of 7.1% to reach USD 10.1 billion by 2035.
The market’s expansion is fueled by the increasing prevalence of prostate cancer, ongoing technological advancements in PSA testing, and the growth of diagnostic laboratory infrastructure worldwide. PSA tests measure the level of a protein produced by the prostate gland, aiding in the early detection of prostate cancer, monitoring disease progression, and assessing treatment outcomes. Technological innovations, such as high-sensitivity assays, automated immunoassay systems, and improved test accuracy, have strengthened clinical confidence in PSA testing. Additional methods, including PSA density, PSA velocity, and reflex testing, enhance diagnostic precision, supporting broader clinical adoption. The industry is moving toward risk-based screening strategies, integrating PSA testing with advanced diagnostic workflows to balance early detection with minimizing overdiagnosis. Factors such as age, ethnicity, family history, baseline PSA levels, and comorbidities increasingly guide testing decisions, making PSA testing more targeted and therapeutically relevant.
The preliminary tests segment held 68% share in 2025 owing to its widespread use as an initial screening tool. Total PSA, free PSA ratio, and first-line screening panels are commonly employed to evaluate cancer risk before recommending invasive procedures. These tests are cost-effective, accessible, and non-invasive, helping clinicians stratify patients and avoid unnecessary biopsies, thereby supporting safer clinical decisions.
The prostate cancer screening segment held a 53.5% share in 2025 and is projected to reach USD 5.1 billion through 2035. PSA testing continues to play a crucial role in early detection, particularly in aging populations, driving its adoption in both targeted and population-based screening programs. Government and institutional support in organized screening initiatives reduces financial and logistical barriers, further increasing test uptake.
North America Prostate-Specific Antigen Test Market accounted for 36.9% share in 2025, driven by the high incidence of prostate cancer, an aging male population, and strong awareness of early detection. Hospitals, specialty clinics, and diagnostic laboratories routinely incorporate PSA testing into standard screening programs. Advanced healthcare infrastructure, including state-of-the-art laboratories and point-of-care facilities, along with high investment in next-generation assays, facilitates rapid adoption and widespread availability of PSA tests in the region.
Key players in the Global Prostate-Specific Antigen Test Market include Abbott, AdvaCare Pharma, Beckman Coulter, BIOMÉRIEUX, CTK Biotech, DiaSorin, Fujirebio, Intec, KOELIS, Labcorp, mdxhealth, Myriad Genetics, OPKO Health, Roche, and SIEMENS Healthineers. Companies in the Global Prostate-Specific Antigen Test Market are employing multiple strategies to strengthen their market foothold. They focus on product innovation, developing highly sensitive, automated, and user-friendly assays for accurate early detection and monitoring. Strategic partnerships with hospitals, diagnostic labs, and healthcare networks expand distribution and adoption. Investment in R&D ensures next-generation technologies, improved assay performance, and regulatory compliance. Geographic expansion into high-growth regions increases market penetration, while marketing campaigns emphasize accuracy, reliability, and clinical relevance. Firms also provide training and technical support to laboratories and clinicians to enhance usage and build long-term customer loyalty, thereby solidifying their competitive positioning.
This product will be delivered within 2-4 business days.
The market’s expansion is fueled by the increasing prevalence of prostate cancer, ongoing technological advancements in PSA testing, and the growth of diagnostic laboratory infrastructure worldwide. PSA tests measure the level of a protein produced by the prostate gland, aiding in the early detection of prostate cancer, monitoring disease progression, and assessing treatment outcomes. Technological innovations, such as high-sensitivity assays, automated immunoassay systems, and improved test accuracy, have strengthened clinical confidence in PSA testing. Additional methods, including PSA density, PSA velocity, and reflex testing, enhance diagnostic precision, supporting broader clinical adoption. The industry is moving toward risk-based screening strategies, integrating PSA testing with advanced diagnostic workflows to balance early detection with minimizing overdiagnosis. Factors such as age, ethnicity, family history, baseline PSA levels, and comorbidities increasingly guide testing decisions, making PSA testing more targeted and therapeutically relevant.
The preliminary tests segment held 68% share in 2025 owing to its widespread use as an initial screening tool. Total PSA, free PSA ratio, and first-line screening panels are commonly employed to evaluate cancer risk before recommending invasive procedures. These tests are cost-effective, accessible, and non-invasive, helping clinicians stratify patients and avoid unnecessary biopsies, thereby supporting safer clinical decisions.
The prostate cancer screening segment held a 53.5% share in 2025 and is projected to reach USD 5.1 billion through 2035. PSA testing continues to play a crucial role in early detection, particularly in aging populations, driving its adoption in both targeted and population-based screening programs. Government and institutional support in organized screening initiatives reduces financial and logistical barriers, further increasing test uptake.
North America Prostate-Specific Antigen Test Market accounted for 36.9% share in 2025, driven by the high incidence of prostate cancer, an aging male population, and strong awareness of early detection. Hospitals, specialty clinics, and diagnostic laboratories routinely incorporate PSA testing into standard screening programs. Advanced healthcare infrastructure, including state-of-the-art laboratories and point-of-care facilities, along with high investment in next-generation assays, facilitates rapid adoption and widespread availability of PSA tests in the region.
Key players in the Global Prostate-Specific Antigen Test Market include Abbott, AdvaCare Pharma, Beckman Coulter, BIOMÉRIEUX, CTK Biotech, DiaSorin, Fujirebio, Intec, KOELIS, Labcorp, mdxhealth, Myriad Genetics, OPKO Health, Roche, and SIEMENS Healthineers. Companies in the Global Prostate-Specific Antigen Test Market are employing multiple strategies to strengthen their market foothold. They focus on product innovation, developing highly sensitive, automated, and user-friendly assays for accurate early detection and monitoring. Strategic partnerships with hospitals, diagnostic labs, and healthcare networks expand distribution and adoption. Investment in R&D ensures next-generation technologies, improved assay performance, and regulatory compliance. Geographic expansion into high-growth regions increases market penetration, while marketing campaigns emphasize accuracy, reliability, and clinical relevance. Firms also provide training and technical support to laboratories and clinicians to enhance usage and build long-term customer loyalty, thereby solidifying their competitive positioning.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Product, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
The companies profiled in this Prostate-Specific Antigen Test market report include:- Abbott
- AdvaCare Pharma
- Beckman Coulter
- BIOMÉRIEUX
- CTK Biotech
- DiaSorin
- Fujirebio
- Intec
- KOELIS
- Labcorp
- mdxhealth
- Myriad Genetics
- OPKO Health
- Roche
- SIEMENS Healthineers
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | March 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 5.1 Billion |
| Forecasted Market Value ( USD | $ 10.1 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
